Sab biotherapeutics to present at the oppenheimer 34th annual healthcare life sciences conference

Sioux falls, s.d., feb. 08, 2024 (globe newswire) -- sab biotherapeutics, inc. (nasdaq: sabs), (“sab” or the “company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced samuel j. reich, the company's chairman and ceo, will present an overview of the company at the oppenheimer 34th annual healthcare life sciences conference on tuesday, february 13, 2024 at 1:20 pm est.
SABS Ratings Summary
SABS Quant Ranking